View More Recent Stories

Feb 18, 2025 04:03PM Halozyme Therapeutics (HALO) Tops Q4 EPS by 11c, provides guidance

Feb 13, 2025 04:48PM Halozyme director Connie Matsui to exit board

Feb 4, 2025 06:39AM H.C. Wainwright Reiterates Buy Rating on Halozyme Therapeutics (HALO)

Feb 3, 2025 07:31AM Halozyme Therapeutics (HALO): CHMP Issues Positive Opinion for Subcutaneous RYBREVANT Co-Formulated with ENHANZE® for the Treatment of Patients with Advanced EGFR-Mutated NSCLC

Jan 10, 2025 08:00AM Halozyme Therapeutics (HALO) PT Raised to $53 at Piper Sandler; ''25+ Guidance Higher As Wave 3 Launches Take Shape'

Dec 30, 2024 06:55AM H.C. Wainwright Reiterates Buy Rating on Halozyme Therapeutics (HALO)

Dec 30, 2024 06:46AM Halozyme Therapeutics (HALO) Announces argenx's VYDURA with ENHANZE was Granted Regulatory Approval in Japan

Dec 30, 2024 06:31AM Halozyme (HALO) Announces FDA Approval of Bristol Myers Squibb's Opdivo Qvantig™ with ENHANZE® for Subcutaneous Use in Most Previously Approved Adult Solid Tumor Opdivo® (nivolumab) Indications

Dec 18, 2024 06:47AM H.C. Wainwright Reiterates Buy Rating on Halozyme Therapeutics (HALO)

Nov 25, 2024 06:43AM H.C. Wainwright Reiterates Buy Rating on Halozyme Therapeutics (HALO)

Nov 22, 2024 11:22AM Evotec SE (EVO) Comment on Withdrawn Non-Binding Offer from Halozyme (HALO)

Nov 22, 2024 08:35AM Halozyme Therapeutics (HALO) Withdraws Proposal to Acquire Evotec (EVO) Following Evotec's Unwillingness to Engage in Discussions

Nov 19, 2024 02:38PM Halozyme Therapeutics (HALO) call put ratio 6.1 calls to 1 put with focus on March 50 and 60 calls as share price up 5.4%

Nov 18, 2024 07:03AM Halozyme Therapeutics (HALO) Provides Update on Non-Binding Proposal to Combine with Evotec (EVO)

Nov 15, 2024 07:40AM Piper Sandler Reiterates Neutral Rating on Halozyme Therapeutics (HALO)

Nov 14, 2024 04:26PM After-hours movers: Applied Materials, Domino's Pizza, Evotec

Nov 14, 2024 04:16PM Halozyme Therapeutics (HALO) Confirms Proposal to Combine with Evotec (EVO) for €11.00 Per Share in an All-Cash Transaction

Nov 14, 2024 02:09PM Evotec (EVO) Is Said To Attract Takeover Interest From Halozyme (HALO) - Bloomberg

Nov 4, 2024 08:43AM Halozyme Therapeutics (HALO) PT Raised to $52 at Piper Sandler

Nov 4, 2024 06:46AM Halozyme Therapeutics (HALO) PT Raised to $68 at H.C. Wainwright

Nov 1, 2024 07:21AM Halozyme Therapeutics (HALO) PT Raised to $58 at Leerink Partners

Oct 31, 2024 04:03PM Halozyme Therapeutics (HALO) Tops Q3 EPS by 31c, provides guidance

Oct 25, 2024 08:04AM H.C. Wainwright Reiterates Buy Rating on Halozyme Therapeutics (HALO)

Oct 24, 2024 06:31AM Halozyme Therapeutics (HALO) Provides Update on Licensee Co-formulation Patent Hearing in Europe

Oct 18, 2024 08:19AM TD Cowen Reiterates Buy Rating on Halozyme Therapeutics (HALO)

Oct 10, 2024 08:52AM TD Cowen Reiterates Buy Rating on Halozyme Therapeutics (HALO)

Oct 4, 2024 06:37AM H.C. Wainwright Reiterates Buy Rating on Halozyme Therapeutics (HALO)

Oct 4, 2024 05:53AM Leerink Partners Reiterates Market Perform Rating on Halozyme Therapeutics (HALO)

Oct 3, 2024 02:18PM TD Cowen Reiterates Buy Rating on Halozyme Therapeutics (HALO)

Oct 3, 2024 08:01AM Halozyme Therapeutics (HALO) Announces Expansion of Global Collaboration and License Agreement with argenx for ENHANZE

Sep 19, 2024 02:44AM JPMorgan Downgrades Halozyme Therapeutics (HALO) to Neutral

Sep 16, 2024 07:00AM H.C. Wainwright Reiterates Buy Rating on Halozyme Therapeutics (HALO)

Sep 13, 2024 01:31PM Halozyme Therapeutics (HALO) Announces FDA Approval of Roche's Subcutaneous OCREVUS ZUNOVO with ENHANZE

Sep 13, 2024 06:42AM H.C. Wainwright Reiterates Buy Rating on Halozyme Therapeutics (HALO)

Aug 7, 2024 10:25AM Halozyme Therapeutics (HALO) PT Raised to $65 at TD Cowen

Aug 6, 2024 04:40PM Halozyme Therapeutics (HALO) Tops Q2 EPS by 15c ; Offers Guidance

Jul 16, 2024 10:51AM H.C. Wainwright Reiterates Buy Rating on Halozyme Therapeutics (HALO)

Jun 27, 2024 06:37AM H.C. Wainwright Reiterates Buy Rating on Halozyme Therapeutics (HALO)

Jun 25, 2024 07:39AM Halozyme Therapeutics (HALO) PT Raised to $60 at Benchmark

Jun 24, 2024 06:35AM H.C. Wainwright Reiterates Buy Rating on Halozyme Therapeutics (HALO)

View More Recent Stories